Progression‐free survival · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin probably leads to lower progression‐free survival (PFS) compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).
1 finding from 1 review
Overall survival (OS) · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin showed no clear difference in overall survival (OS) compared with tri‐weekly paclitaxel plus carboplatin (high certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin showed no clear difference in haematological adverse event: Grade 3/4 neutropenia compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).
1 finding from 1 review
Grade 3 and 4 hematological adverse events (AE) ‐ anemia · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin leads to higher haematological adverse event: Grade 3/4 anaemia compared with tri‐weekly paclitaxel plus carboplatin (high certainty).
1 finding from 1 review
Neurological adverse event: Grade 3/4 neuropathy, not otherwise specified · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin showed no clear difference in neurological adverse event: Grade 3/4 neuropathy, not otherwise… compared with tri‐weekly paclitaxel plus carboplatin (low certainty).
1 finding from 1 review
Overall survival · women with recurrent epithelial ovarian cancer
It is very uncertain whether weekly paclitaxel changes overall survival compared with three‐weekly paclitaxel (very low certainty).
1 finding from 1 review
Response rate · women with recurrent epithelial ovarian cancer
It is very uncertain whether weekly paclitaxel changes response rate compared with three‐weekly paclitaxel (very low certainty).
1 finding from 1 review
Response rate ‐ platinum‐sensitive · women with recurrent epithelial ovarian cancer
It is very uncertain whether weekly paclitaxel changes response rate ‐ platinum‐sensitive compared with three‐weekly paclitaxel (very low certainty).
1 finding from 1 review
Response rate ‐ platinum‐resistant · women with recurrent epithelial ovarian cancer
It is very uncertain whether weekly paclitaxel changes response rate ‐ platinum‐resistant compared with three‐weekly paclitaxel (very low certainty).
1 finding from 1 review
Quality of life ‐ not reported · women with recurrent epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · women with recurrent epithelial ovarian cancer
It is very uncertain whether weekly paclitaxel changes progression‐free survival compared with three‐weekly paclitaxel (very low certainty).
1 finding from 1 review
Neurotoxicity · women with recurrent epithelial ovarian cancer
It is very uncertain whether weekly paclitaxel changes neurotoxicity compared with three‐weekly paclitaxel (very low certainty).
1 finding from 1 review
Neutropenia · women with recurrent epithelial ovarian cancer
Weekly paclitaxel may leads to lower neutropenia compared with three‐weekly paclitaxel (low certainty).
1 finding from 1 review
Alopecia · women with recurrent epithelial ovarian cancer
Weekly paclitaxel may leads to lower alopecia compared with three‐weekly paclitaxel (low certainty).
1 finding from 1 review